LZTS1 Antibody
-
中文名稱：LZTS1兔多克隆抗體
-
貨號：CSB-PA013291GA01HU
-
規格：￥3,900
-
其他：
產品詳情
-
Uniprot No.：
-
基因名：LZTS1
-
別名：F37 antibody; F37/esophageal cancer related gene coding leucine zipper motif antibody; F37/esophageal cancer-related gene-coding leucine-zipper motif antibody; Fez1 antibody; Leucine zipper putative tumor suppressor 1 antibody; Lzts1 antibody; LZTS1_HUMAN antibody; Psdzip70 antibody
-
宿主：Rabbit
-
反應種屬：Human,Mouse,Rat
-
免疫原：Human LZTS1
-
免疫原種屬：Homo sapiens (Human)
-
抗體亞型：IgG
-
純化方式：Antigen Affinity purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
-
產品提供形式：Liquid
-
應用范圍：ELISA,WB,IF
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Involved in the regulation of cell growth. May stabilize the active CDC2-cyclin B1 complex and thereby contribute to the regulation of the cell cycle and the prevention of uncontrolled cell proliferation. May act as a tumor suppressor.
-
基因功能參考文獻：
- missense variant in the LZTS1 gene was identified in two Ehlers-Danlos syndrome patients in an extended family. PMID: 26504261
- LZTS1 promoter was frequently methylated in IMPC samples. PMID: 25813822
- Compared with the normal hepatocyte cells, LZTS1 expression in hepatocellular carcinoma cells was significantly lower PMID: 26653561
- miR-135b expression inversely correlated with LZTS1 staining intensity and the Cutaneous Squamous Cell Carcinoma grade. PMID: 25938461
- Suggest that LZTS1 plays a potential tumor suppressor role in colorectal cancer progression and represents a valuable clinical prognostic marker of this disease. PMID: 25667121
- Lzts1 was significantly downregulated in breast cancer samples and its deregulation was associated with a higher incidence of tumor recurrence, and to a worse overall survival. PMID: 24448468
- miR-214 functions as an onco-miRNA in osteosarcoma, and its oncogenic effects are mediated chiefly through downregulation of LZTS1 PMID: 24802407
- Expression of miR-135b, LZTS1, LATS2 and nuclear TAZ predicts poor outcomes of non-small-cell lung cancer. PMID: 23695671
- Lower levels of leucine zipper putative tumor suppressor 1 correlated with high histologic grade, lymph node metastasis, and poor prognosis. PMID: 21419475
- variation in the germline sequence is associated with prostate cancer risk PMID: 12377406
- Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity is associated with oral squamous cell carcinomas PMID: 12851677
- Forced expression of LZTS1 in metastasizing uveal melanoma cells inhibited their motility and invasion, whereas depletion of LZTS1 increased their motility. PMID: 18559591
- Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis. PMID: 18686028
- The reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma. PMID: 19885841
顯示更多
收起更多
-
相關疾病：Esophageal cancer (ESCR)
-
亞細胞定位：Cytoplasm. Cell membrane. Cell projection, dendritic spine. Cell junction, synapse, postsynaptic density. Cell junction, synapse.
-
蛋白家族：LZTS family
-
組織特異性：Highly expressed in testis, prostate, spleen, thymus, ovary and brain. Detected at lower levels in heart, placenta, small intestine, colon, liver, kidney, skeletal muscle and pancreas. Not detectable in primary tumors from breast and prostate and in many
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
